Boston Scientific was the worst performer in the S&P 500 Wednesday after the medical-device maker beat earnings expectations but offered a disappointing outlook for the current quarter.

Few analysts foresaw the disappointing results and profit forecast that sent Boston Scientific Corp.’s shares plummeting nearly 20% this week. Even fewer have given up on their bullish calls since. It ...

In October, Boston Scientific announced plans to dive into the peripheral nerve stimulation space through the acquisition of medtech company Nalu Medical. Boston Scientific has been a Nalu investor ...

Boston Scientific (BSX), a leading global player in medical devices, announced solid Q4 earnings but offered 2026 guidance that slightly fell short of elevated investor expectations. This response was ...

The stock slid 18% on softer EP sales and initial 2026 targets, leaving investors focused on March 28 CHAMPION-AF results and China-driven growth. Worries centered on EP, where Q4 revenue was $890 ...

The Boston Scientific Analyst: Analyst Mike Matson maintained a Buy rating, but slashed the price target from $121 to $97. The Boston Scientific Thesis: The company reported revenue of $5.286 billion ...

Boston Scientific expects first quarter 2026 reported revenue growth to be in a range of 10.5% to 12% versus first quarter 2025. Excluding foreign exchange, operational and organic revenue growth for ...

Boston Scientific grew sales and adjusted earnings per share by 16% and 14% in the fourth quarter. However, the company's guidance underwhelmed the market. Ultimately, Boston Scientific's earnings ...

Feb 4 (Reuters) - Boston Scientific (BSX.N), opens new tab on Wednesday reported lower-than-expected quarterly sales in its key electrophysiology division, dragging the medical device maker's shares ...

The company's earnings came in at $672 million, or $0.45 per share. This compares with $566 million, or $0.38 per share, last year. Excluding items, Boston Scientific Corp reported adjusted earnings ...

To supplement our unaudited consolidated financial statements presented on a GAAP basis, we disclose certain non-GAAP financial measures, including adjusted net income (loss), adjusted net income ...

The medical technology giant reported adjusted earnings of 80 cents, beating the consensus of 78 cents and the management guidance of 77-79 cents. Sales increased 15. ...